Taylor & Francis Group
Browse
kaup_a_2062872_sm2859.doc (102.92 MB)

Increased mitophagy protects cochlear hair cells from aminoglycoside-induced damage

Download (102.92 MB)
journal contribution
posted on 2022-04-26, 12:40 authored by Yuhua Zhang, Qiaojun Fang, Hongfeng Wang, Jieyu Qi, Shan Sun, Menghui Liao, Yunhao Wu, Yangnan Hu, Pei Jiang, Cheng Cheng, Xiaoyun Qian, Mingliang Tang, Wei Cao, Shang Xiang, Chen Zhang, Jianming Yang, Xia Gao, Zheng Ying, Renjie Chai

Aminoglycosides exhibit ototoxicity by damaging mitochondria, which in turn generate reactive oxygen species that induce hair cell death and subsequent hearing loss. It is well known that damaged mitochondria are degraded by mitophagy, an important mitochondrial quality control system that maintains mitochondrial homeostasis and ensures cell survival. However, it is unclear whether dysregulation of mitophagy contributes to aminoglycoside-induced hair cell injury. In the current study, we found that PINK1-PRKN-mediated mitophagy was impaired in neomycin-treated hair cells. Our data suggested that mitochondrial recruitment of PRKN and phagophore recognition of damaged mitochondria during mitophagy were blocked following neomycin treatment. In addition, the degradation of damaged mitochondria by lysosomes was significantly decreased as indicated by the mitophagic flux reporter mt-mKeima. Moreover, we demonstrated that neomycin disrupted mitophagy through transcriptional inhibition of Pink1 expression, the key initiator of mitophagy. Moreover, we found that neomycin impaired mitophagy by inducing ATF3 expression. Importantly, treatment with a mitophagy activator could rescue neomycin-treated hair cells by increasing mitophagy, indicating that genetic modulation or drug intervention in mitophagy may have therapeutic potential for aminoglycoside-induced hearing loss.

Abbreviations: AAV: adeno-associated virus; ABR: auditory brainstem response; ATF3: activating transcription factor 3; ATOH1/MATH1: atonal bHLH transcription factor 1; BafA1: bafilomycin A1; CCCP: carbonyl cyanide m-chlorophenyl hydrazone; COX4I1/COXIV: cytochrome c oxidase subunit 4I1; CTBP2/RIBEYE: C-terminal binding protein 2; DFP: deferiprone; EGFP: enhanced green fluorescent protein; FOXO3: forkhead box O3; GRIA2/GLUR2: glutamate receptor, ionotropic, AMPA2 (alpha 2); HC: hair cell; HSPD1/HSP60: heat shock protein 1 (chaperonin); IHC: inner hair cell; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; MYO7A: myosin VIIA; OPTN: optineurin; OMM: outer mitochondrial membrane; PRKN: parkin RBR E3 ubiquitin protein ligase; PINK1: PTEN induced putative kinase 1; RT-qPCR: real-time quantitative polymerase chain reaction; TOMM20/TOM20: translocase of outer mitochondrial membrane 20; TUNEL: Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling; USP30: ubiquitin specific peptidase 30; XBP1: X-box binding protein 1.

Funding

This work was supported by grants from the National Key R&D Program of China (2017YFA0105201; 2021YFA1101300; 2020YFA0112503), the Strategic Priority Research Program of the Chinese Academy of Science (strategic priority research program of the chinese academy of XDA16010303), the National Natural Science Foundation of China (Nos. 81771019, 81970884, 81970882, 81870721, 82071055), the Natural Science Foundation of Jiangsu Province BE2019711), Jiangsu Provincial Key Research and Development (jiangsu provincial key research and development BE2018605), Science and Technology Department of Sichuan Province (No. 2021YFS0371), the Postgraduate Research & Practice Innovation Program of Jiangsu Province (postgraduate research & practice innovation program of jiangsu province KYCX19_0057), the Jiangsu Province Natural Science Foundation (jiangsu province natural science foundation BK20190121), the National Science Foundation for Young Scientists of China (81900941, 82000986), the Shenzhen Fundamental Research Program (No. JCYJ20190814093401920, JCYJ20210324125608022); the China Postdoctoral Science Foundation (2020M681451), a project funded by Jiangsu Key Laboratory of Neuropsychiatric Diseases (project funded by jiangsu key laboratory of neuropsychiatric diseases BM2013003), and a project funded by the Priority Academic Program Development of the Jiangsu Higher Education Institutes (project funded by the priority academic program development of the jiangsu higher education institutes PAPD), the Cooperative research promotion plan of basic medicine and clinical medicine of Anhui Medical University (2020XKjT036), Jiangsu Postdoctoral Research Funding Program (Jiangsu Postdoctoral Research Foundation 2021K017A).

History